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VCAN-Related Vitreoretinopathy
Abstract
Disease characteristics. VCAN-related vitreoretinopathy, which includes Wagner syndrome and erosive
vitreoretinopathy (ERVR), is characterized by “optically empty vitreous” on slit-lamp examination and
avascular vitreous strands and veils, mild or occasionally moderate to severe myopia, presenile cataract,
night blindness of variable degree associated with progressive chorioretinal atrophy, retinal detachment
at advanced stages of the disease, and reduced visual acuity. Systemic abnormalities are not observed.
The first signs usually become apparent during early adolescence, but onset can be as early as age two
years. Diagnosis/testing. The clinical diagnosis of VCAN-related vitreoretinopathy is established based
on typical clinical findings and a family history consistent with autosomal dominant inheritance. VCAN
(previously CSPG2) is the only gene known to be associated with Wagner syndrome and ERVR.
Molecular genetic testing is available on a clinical basis. Management. Treatment of manifestations:
Refractive error is corrected by spectacles or contact lenses; visually disabling cataract is treated by
cataract surgery, preferably by an experienced surgeon. Retinal breaks without retinal detachment are
treated with laser retinopexy or cryocoagulation. Vitreoretinal surgery is indicated for retinal
detachment, vitreoretinal traction involving the macula, or epiretinal membranes involving the macula.
Surveillance: annual ophthalmologic examination by a vitreoretinal specialist. Testing of relatives at
risk: for the purpose of early diagnosis and treatment of ophthalmologic complications in at-risk
relatives: molecular genetic testing if the disease-causing mutation has been identified in the family;
otherwise, ophthalmologic evaluation. Genetic counseling. VCAN-related vitreoretinopathy is inherited
in an autosomal dominant manner. Most individuals diagnosed with VCAN-related vitreoretinopathy
have an affected parent. Each child of an affected individual has a 50% chance of inheriting the
mutation. Although no laboratories listed in the GeneTests Laboratory Directory offer molecular genetic
testing for prenatal diagnosis of VCAN-related vitreoretinopathy, such
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Summary 
Disease characteristics. VCAN-related vitreoretinopathy, which includes Wagner syndrome and erosive vitreoretinopathy (ERVR), is 
characterized by “optically empty vitreous” on slit-lamp examination and avascular vitreous strands and veils, mild or occasionally moderate
to severe myopia, presenile cataract, night blindness of variable degree associated with progressive chorioretinal atrophy, retinal 
detachment at advanced stages of the disease, and reduced visual acuity. Systemic abnormalities are not observed. The first signs usually 
become apparent during early adolescence, but onset can be as early as age two years. 
Diagnosis/testing. The clinical diagnosis of VCAN-related vitreoretinopathy is established based on typical clinical findings and a family 
history consistent with autosomal dominant inheritance. VCAN (previously CSPG2) is the only gene known to be associated with Wagner 
syndrome and ERVR. Molecular genetic testing is available on a clinical basis. 
Management. Treatment of manifestations: Refractive error is corrected by spectacles or contact lenses; visually disabling cataract is 
treated by cataract surgery, preferably by an experienced surgeon. Retinal breaks without retinal detachment are treated with laser 
retinopexy or cryocoagulation. Vitreoretinal surgery is indicated for retinal detachment, vitreoretinal traction involving the macula, or 
epiretinal membranes involving the macula. Surveillance: annual ophthalmologic examination by a vitreoretinal specialist. Testing of 
relatives at risk: for the purpose of early diagnosis and treatment of ophthalmologic complications in at-risk relatives: molecular genetic 
testing if the disease-causing mutation has been identified in the family; otherwise, ophthalmologic evaluation. 
Genetic counseling. VCAN-related vitreoretinopathy is inherited in an autosomal dominant manner. Most individuals diagnosed with 
VCAN-related vitreoretinopathy have an affected parent. Each child of an affected individual has a 50% chance of inheriting the mutation. 
Although no laboratories listed in the GeneTests Laboratory Directory offer molecular genetic testing for prenatal diagnosis of VCAN-related 
vitreoretinopathy, such testing may be possible through laboratories offering custom prenatal testing for families with a known disease-
causing mutation. 
Diagnosis 
Clinical Diagnosis 
VCAN-related vitreoretinopathy is characterized by: 
z “Optically empty vitreous” on slit-lamp examination and avascular vitreous strands and veils 
z Mild or occasionally moderate to severe myopia 
z Presenile cataract 
z Night blindness of variable degree associated with progressive chorioretinal atrophy 
z Retinal detachment at advanced stages of the disease 
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z Reduced visual acuity resulting from the above manifestations 
z Absence of systemic abnormalities 
The clinical diagnosis of VCAN-related vitreoretinopathy is established based on typical clinical findings and a family history consistent with 
autosomal dominant inheritance. The presence of several affected family members facilitates diagnosis by identifying the mode of 
inheritance and spectrum of ocular findings among affected family members at different ages. In general, it is the pattern of ocular findings 
in an individual or a family rather than a specific ocular finding that helps establish the diagnosis. Establishing the diagnosis may be more 
difficult in a simplex case (i.e., a single occurrence in a family). 
Molecular Genetic Testing 
GeneReviews designates a molecular genetic test as clinically available only if the test is listed in the GeneTests Laboratory Directory by 
either a US CLIA-licensed laboratory or a non-US clinical laboratory. GeneTests does not verify laboratory-submitted information or warrant 
any aspect of a laboratory's licensure or performance. Clinicians must communicate directly with the laboratories to verify information.—ED.
Gene. VCAN (previously CSPG2), encoding the large extracellular matrix proteoglycan versican, is the only gene currently known to be 
associated with Wagner syndrome and erosive vitreoretinopathy (ERVR) [Miyamoto et al 2005, Kloeckener-Gruissem et al 2006, Meredith et
al 2006, Mukhopadhyay et al 2006]. 
Clinical testing 
z Sequence analysis. Sequence analysis of the entire VCAN coding region and flanking introns performed in ten families with 
either Wagner syndrome or ERVR identified mutations in eight; in the two remaining families no presumably disease-related 
mutations were found [Miyamoto et al 2005, Kloeckener-Gruissem et al 2006, Meredith et al 2006, Mukhopadhyay et al 
2006]. 
Table1 summarizes molecular genetic testing for this disorder. 
Table 1. Molecular Genetic Testing Used in VCAN-Related Vitreoretinopathy 
1. In eight of ten families with VCAN-related vitreoretinopathy, sequence analysis of the entire VCAN coding region and flanking introns identified 
mutations; in two families no mutation was found [Miyamoto et al 2005, Kloeckener-Gruissem et al 2006, Meredith et al 2006, Mukhopadhyay et al 2006]. 
Interpretation of test results. For issues to consider in interpretation of sequence analysis results, click here. 
Testing Strategy 
Establishing the diagnosis in a proband 
z Because all VCAN mutations to date associated with Wagner syndrome and ERVR are found in the splice acceptor or splice 
donor site of introns 7 and 8, respectively, sequencing of this DNA region is recommended as a first step. 
z If no mutation is found, sequencing of the entire VCAN coding region is recommended. 
Of note, the presence of characteristic connective tissue abnormalities in the patient or relatives could prompt genetic testing for Stickler 
syndrome rather than or in addition to testing for VCAN mutations. See Differential Diagnosis. 
Prenatal diagnosis and preimplantation genetic diagnosis (PGD) for at-risk pregnancies require prior identification of the disease-
causing mutation in the family. 
Genetically Related (Allelic) Disorders 
No phenotypes other than VCAN-related vitreoretinopathy have been reported to be associated with mutations in VCAN. 
Clinical Description 
Natural History 
VCAN-related vitreoretinopathy comprises the phenotypic continuum of Wagner vitreoretinal degeneration (Wagner syndrome) and erosive 
vitreoretinopathy (ERVR), two disorders that were previously thought to be distinct entities based on clinical findings. Wagner syndrome, 
Gene Symbol Test Method Mutations Detected Mutation Detection Frequency by Test Method Test Availability
VCAN
Sequence 
analysis
Sequence 
variants
8/10 families with VCAN-related vitreoretinopathy 1 Clinical 
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the first reported inherited vitreoretinal degeneration, was described by Wagner [1938]. ERVR was described in 1994 as a new clinical entity
with some features that overlapped with Wagner syndrome [Brown et al 1994]. 
Vitreoretinal degeneration 
As described by Wagner [1938], the hallmark of VCAN-related vitreoretinopathy is progressive degenerative changes of the vitreous 
(syneresis) and the vitreoretinal interface beginning at a young age. Syneresis can lead to massive liquefaction of the vitreous such that on 
slit-lamp examination the vitreous cavity appears optically empty ("empty vitreous") with pockets of liquefied vitreous that are usually lined 
by avascular strands and veils. Preretinal vitreous membranes that span the whole equator of the eye are characteristic. Ocular changes 
show considerable inter- and intrafamilial variability. 
The first signs usually become apparent during early adolescence, but onset can be as early as age two years [Miyamoto et al 2005]. 
No gender-specific difference in the occurrence or frequency of any particular ocular features has been observed. 
The vitreous degeneration, which is assumed to be the primary pathology, leads to a number of secondary changes, including presenile 
cataract, degeneration and atrophy of the retina, and the underlying retinal pigment epithelium (RPE) and choroid, and retinal detachment 
[Wagner 1938, Jansen 1962, Graemiger et al 1995, Zech et al 1999, Miyamoto et al 2005, Meredith et al 2006, Mukhopadhyay et al 2006]. 
Common ocular features (occurring in ≤60% of affected individuals): 
Myopic refractive error (nearsightedness) results from axial myopia (a developmental mismatch of the refractive power and length of the 
globe) and/or index myopia (a change in the refractive index of the progressively cataractous lens). Axial myopia is common, although 
severity varies. In the family reported by Wagner, most affected members had mild myopia and only a few had moderate to severe myopia. 
In contrast, in the Dutch family all members had high myopia with astigmatism [Jansen 1962]. 
Presenile cataract (progressive loss of transparency of the ocular lens) is a common finding and a common cause of decline in visual 
acuity over time. The types of cataract vary. Small spherical opacities and posterior subcapsular cataract affected 43% of eyes in the 
original family reported by Wagner [Graemiger et al 1995]. In the Dutch families, cataract types included moderate cortical cataract, 
anterior and posterior cortical cataract, and posterior subcapsular cataract [Mukhopadhyay et al 2006]. Nuclear cataract without any 
posterior subcapsular opacity was described in a British family [Meredith et al 2006]. 
In a Japanese family, approximately 50% of affected individuals underwent cataract surgery; the oldest was age 35 years [Miyamoto et al 
2005]. In a French family, cataract affected 55% of individuals [Zech et al 1999]. Of note, even after cataract extraction and correction of 
the refractive error, visual acuity was not normal, typically ranging from 6/12 (20/40) to 6/24 (20/80). 
Nonspecific reactive changes of the retinal pigment epithelium and overlying retina (pigment condensation, vascular sheathing, 
pigmented lattice degeneration, and later chorioretinal atrophy in the retinal periphery) occur. Affected individuals may experience 
nyctalopia (night blindness) and visual field constriction that are not as severe as those seen in retinitis pigmentosa. Nyctalopia may or may 
not progress. In some cases the chorioretinal atrophy is so severe that it resembles choroideremia. 
The full-field electroretinogram (ERG) becomes attenuated. Typically both the amplitudes of the a-waves (response of the photoreceptor 
layer) and the b-waves (response of the bipolar cell layer) are reduced. The rod and cone systems (as measured by the scotopic and 
photopic response, respectively) are affected to varying degrees but in a family-specific manner, as demonstrated by the Swiss family 
originally reported by Wagner, the Japanese family, and the British family [Graemiger et al 1995, Miyamoto et al 2005, Meredith et al 
2006]. No ERG measurements were reported from the French and Dutch families [Zech et al 1999, Mukhopadhyay et al 2006]. 
Abnormal retinal vessels or poor vascularization of the peripheral retina were found in approximately 50% of individuals from the 
family reported by Wagner [Graemiger et al 1995], but only in a few individuals of the Dutch families [Mukhopadhyay et al 2006]. No 
details about retinal vessel characteristics were given for the other reported families [Zech et al 1999, Miyamoto et al 2005, Meredith et al 
2006]. 
Retinal detachment is a finding that increases with age. Caused by shrinkage of the preretinal membranes and the vitreous strands and 
veils, retinal detachment is either tractional or rhegmatogenous. 
z Tractional retinal detachment is caused by tangential shortening of the adhering membranes. The detached retina is rigid; 
successful surgical repair requires meticulous removal of the membranes and vitreoretinal adhesions and, most often, 
extensive retinotomies to relieve the traction. Tractional retinal detachment is not a particularly common feature of Wagner 
syndrome. 
z Rhegmatogenous retinal detachment is caused by retinal breaks associated with the preretinal membranes. Liquefied vitreous 
fluid enters the potential subretinal space through one or more retinal tears caused by shrinking membranes. The retinal 
detachment is typically bullous; surgical repair primarily relies on closure of all retinal breaks. Of note, rhegmatogenous 
retinal detachment associated with hereditary vitreoretinal degeneration in young individuals in a considerable number of 
cases presents with only minor changes of the vitreous. Consequently, large retinal tears in young persons should raise the 
suspicion of a hereditary disease, and should prompt examination of other family members and eventually molecular genetic 
analysis. 
In the original publication by Wagner the incidence of retinal detachment at age 20 years was one in four, whereas in the Dutch pedigrees 
published by Jansen bilateral retinal detachment was a frequent finding at a young age. Of note, follow-up publications of the original 
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Wagner pedigree reported an incidence of retinal detachment more than one in two. Of the few retinal detachments described in the Swiss 
family reported originally by Wagner and the Dutch families reported by Jansen, some were peripheral tractional [Graemiger et al 1995, 
Mukhopadhyay et al 2006]. In contrast, in the Japanese family reported by Miyamoto et al [2005], most of the retinal detachments were 
rhegmatogenous. No retinal detachments were observed in the only two affected individuals reported in a British family [Meredith et al 
2006]. 
Occasional ocular features 
The following features have been reported rarely. Some may not be part of VCAN-related vitreoretinopathy but rather occur coincidentally. 
Spherophakia, a spherical deformation of the ocular lens, has been observed sporadically in persons with VCAN-related vitreoretinopathy 
[Graemiger et al 1995]. 
Cataract can induce a change of the refractive index of the lens nucleus, further attenuating the myopic refractive error (index myopia). 
Posterior vitreous detachment (PVD), detachment of the posterior vitreous membrane from the retinal surface, is caused by shrinkage 
of the vitreous body and the pathological vitreoretinal interface. In contrast to the usual age-related PVD, the PVD in VCAN-related 
vitreoretinopathy initially affects the peripheral rather than the central posterior vitreous. None of the individuals from the original family 
described by Wagner or the French family showed PVD [Graemiger et al 1995, Zech et al 1999]. 
Ectopic fovea, manifesting as an increased angle kappa (the angle between the visual axis and the pupillary axis), has occasionally been 
reported [Graemiger et al 1995, Miyamoto et al 2005, Meredith et al 2006]. 
Phthisis bulbi (painful shrinking of the ocular globe as a result of loss of intraocular pressure) can occur and may require enucleation of 
the eye. Retinal detachment that has not been repaired successfully and retinal detachment associated with proliferative retinal 
vitreoretinopathy (PVR) are risk factors for phthisis bulbi. The decrease in intraocular pressure is caused by decreased aqueous production 
by the ciliary body epithelium, which becomes compromised by the pathologic vitreoretinal membranes because of the primary vitreal 
changes, the PVR, or both. 
Synchysis scintillans (bilateral accumulation of cholesterol crystals in the vitreous, which may or may not be associated with recurrent 
vitreous hemorrhage), may or may not occur with increased frequency in VCAN-related vitreoretinopathy, as it was only observed in a few 
older affected individuals [Graemiger et al 1995, Zech et al 1999]. 
Optic atrophy was found in only a few of the older individuals from the original Wagner family. These individuals had advanced 
chorioretinal atrophy, suggesting that optic atrophy is secondary to the massive loss in retinal ganglion cells [Graemiger et al 1995]. 
Glaucoma may not be a common feature of Wagner syndrome, as only a few individuals with VCAN-related vitreoretinopathy have been 
reported with glaucoma, none of them having primary open-angle glaucoma (one had congenital glaucoma, two had chronic angle-closure 
glaucoma, and three had neovascular glaucoma). 
Systemic findings 
To date, no systemic abnormalities associated with VCAN-related vitreoretinopathy have been reported, and consequently VCAN-related 
vitreoretinopathy is considered an isolated vitreoretinal degeneration. 
Note: Recording blood pressure in persons with vitreoretinopathy may reveal possible systemic complications. 
Genotype-Phenotype Correlations 
Because of the highly variable frequency of findings and the low number of mutations identified to date, no definite genotype-phenotype 
correlations have been established so far. 
Penetrance 
Penetrance appears to be complete. Within families reported to date, no unaffected individuals had a VCAN mutation. 
Anticipation 
Anticipation is not observed. 
Nomenclature 
Once the molecular basis of Wagner syndrome, originally described by Wagner in 1938, and ERVR, originally described by Brown and 
colleagues in 1994, was identified, the high similarity of the clinical phenotypes and the fact that both were caused by mutations in the 
same gene led to the conclusion that both were descriptions of the same disorder, which has been called VCAN-related vitreoretinopathy in 
this GeneReview [Brown et al 1994, Brown et al 1995, Mukhopadhyay et al 2006]. 
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The predominantly ocular, or nonsyndromic, phenotype of Stickler syndrome, associated with specific mutations in exon 2 of COL2A1, 
encoding the alpha 1 chain of collagen type II [Richards et al 2000], can readily be distinguished from Wagner syndrome because of its 
distinctive vitreous phenotype [Snead & Yates 1999]. However, some authors have referred to this form of Stickler syndrome as Wagner 
syndrome type II and have designated the VCAN-related phenotype as vitreoretinochoroidopathy (VRCP) Wagner syndrome type I [Gupta 
et al 2002]. 
Syndrome alias: hyaloideoretinal degeneration of Wagner 
Prevalence 
Wagner syndrome is a very rare disorder. After the first Swiss pedigree reported by Wagner in 1938, several additional families, some of 
them very large, have been reported. Including families with ERVR, not more than 50 families or simplex cases of VCAN-related 
vitreoretinopathy have been reported. 
Wagner syndrome has been reported in families of various ethnic backgrounds including Caucasian, Japanese, and Chinese. 
Differential Diagnosis 
For current information on availability of genetic testing for disorders included in this section, see GeneTests Laboratory Directory. —ED. 
Syndromes with overlapping features 
A recent review summarizes the clinical features of inherited vitreoretinopathies and points out the importance of consulting an expert 
ophthalmologist in diagnostic assessment of the disease [Edwards 2008]. 
Autosomal dominant vitreoretinopathies 
Snowflake vitreoretinal degeneration (SVD) (OMIM 193230). Both SVD and VCAN-related vitreoretinopathy exhibit vitreous 
abnormalities including fibrillar condensation, gel liquefaction, and marked thickening of the cortical vitreous. In SVD, however, 
membranous degeneration of the vitreous with avascular strands and veils is not observed. Retinal defects start in the superficial retinal 
layers, whereas in VCAN-related vitreoretinopathy they start in the deep retinal layers and choroid; retinal detachment is uncommon; and 
the retinal crystalline snowflake-like deposits that give the disease its name are common. Mutations in KCNJ13 are causative [Hejtmancik et 
al 2008]. 
Stickler syndrome (OMIM 108300, 184840, 604841). Stickler syndrome, or hereditary arthroophthalmopathy, is most often a systemic 
disorder associated with a skeletal dysplasia (spondyloepiphyseal dysplasia) and craniofacial abnormalities, including cleft palate. Retinal 
detachment is much more common in Stickler syndrome (50%) than in VCAN-related vitreoretinopathy (15%). Abnormal dark adaptation 
associated with alterations in the ERG that is common in VCAN-related vitreoretinopathy has not been described in Stickler syndrome. Two 
different and specific vitreoretinal phenotypes have been described in Stickler syndrome (Stickler syndrome type 1 and type 2). The type 1 
vitreoretinal phenotype is caused by mutations in COL2A1 encoding type II procollagen. For certain mutations in COL2A1, a predominantly 
ocular or nonsyndromic phenotype can result. Usually, however, these patients can be readily distinguished from patients with Wagner 
syndrome because of the specific vitreous anomaly associated with type 1 Stickler syndrome. However, some authors have referred to this 
form of Stickler syndrome as Wagner syndrome type II [Gupta et al 2002]. 
Autosomal dominant vitreoretinochoroidopathy (ADVIRC) (OMIM 193220). Only a few families have been described with 
vitreoretinochoroidopathy (VRCP). Affected individuals show the following findings that seem to progress more slowly than those of VCAN-
related vitreoretinopathy: 
z Fibrillar condensation of the vitreous, but not optically empty vitreous 
z Chorioretinal hyperpigmentation with peripheral pigmentary clumping 
z Macular atrophy 
z Breakdown of the blood retinal barrier (observed in one family) 
z Normal full-field (Ganzfeld) ERG but altered multifocal ERG pattern 
z Cataract 
High myopia and retinal detachment do not seem to be part of VRCP [Oh & Vallar 2006]. Mutations in VMD2, the gene encoding bestrophin, 
are causative. It appears that splicing defects may cause VRCP, whereas mutations in the coding region result in Best disease [Yardley et al 
2004]. 
Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV). Bennett et al [1990] reported a six-generation family 
with an autosomal dominant vitreoretinopathy in which the prevailing clinical features were severe anterior and posterior segment 
inflammation; neovascular proliferations and related complications, in particular tractional retinal detachment and neovascular glaucoma; 
and a selective loss of the b-wave amplitude on the ERG early in the disease. Mutations in VMD2 are causative. ADNIV and ADVIRC may be 
considered to belong to a disease spectrum of VMD2-related autosomal dominant vitreoretinopathies. 
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Autosomal recessive vitreoretinopathies 
Goldmann-Favre syndrome (included in enhanced S-cone syndrome). Mutations in NR2E3 (nuclear receptor subfamily 2, group E, 
member 3) have been identified in Goldmann-Favre syndrome, enhanced S-cone syndrome (ESCS), and clumped pigmentary retinal 
degeneration [Haider et al 2000]. All these clinical entities are usually associated with night blindness and visual field constriction. 
Electroretinography characteristically reveals a severe reduction in rod function and a relatively enhanced function of the short-wavelength-
sensitive cones. 
The classic Goldmann-Favre phenotype includes progressive vitreous changes (vitreous liquefaction and fibrillar strands and veils); night 
blindness and severe reduction in the ERG in early childhood; chorioretinal atrophy and pigmentary retinal degeneration later in the disease 
course resulting in marked visual field loss; retinoschisis in the periphery, macula, or both; presenile cataract; and a hyperopic rather than 
myopic refractive error. 
Although ESCS lacks the marked vitreous changes typical of the Goldmann-Favre phenotype, vitreous cells are a very common feature, and 
more prominent vitreous changes including vitreous opacities, haze, and veils can occur. Peripheral retinal schisis has been observed in 
ESCS, and foveal schisis, eventually associated with cystoid changes, may even be a common feature. The fundus appearance varies, and 
features are overlapping with clumped pigmentary retinal degeneration, in which the retinal pigmentary changes are the most prominent 
feature of the phenotype [Audo et al 2008]. 
Knobloch syndrome (OMIM 267750). Knobloch syndrome is a syndromic vitreoretinopathy in which ocular changes similar to those of 
VCAN-related vitreoretinopathy are associated with occipital encephalocele. Mutations in COL18A1, the gene encoding the alpha 1 chain of 
collagen type 18, are causative [Menzel et al 2004, Keren et al 2007]. 
Management 
Evaluations Following Initial Diagnosis 
To establish the extent of disease in an individual diagnosed with VCAN-related vitreoretinopathy, the following evaluations are 
recommended: 
z Baseline ophthalmologic examination including best corrected visual acuity, assessment of intraocular pressure, slit-lamp 
examination of the anterior segment, and biomicroscopy and indirect ophthalmoscopy of the posterior segment 
z Family history 
z Visual field examination 
z Photographic fundus documentation 
z Optical coherence tomography (OCT), if available. While not mandatory, OCT scan is useful assessing the vitreoretinal 
interface, quantifying atrophic changes of the central retina, and evaluating for cystoid macular edema. 
z ERG examination 
z Orthoptic assessment 
Treatment of Manifestations 
Refractive error is corrected by spectacles or contact lenses. 
Visually disabling cataract is treated by cataract surgery. Phacoemulsification and implantation of an intraocular lens in the capsular bag 
has become the widely adopted standard procedure; however, as emphasized by Edwards, cataract surgery in patients with 
vitreoretinopathy and possibly preceding vitrectomy can be difficult and should be performed by an experienced surgeon [Miyamoto et al 
2005, Edwards 2008]. 
Posterior capsule opacification after cataract surgery is treated with YAG laser capsulotomy. 
Retinal breaks are treated with laser retinopexy or cryocoagulation if no retinal detachment is present. 
Vitreoretinal surgery is indicated for retinal detachment, vitreoretinal traction involving the macula, or epiretinal membranes involving 
the macula. 
Surveillance 
Annual ophthalmologic examination by a vitreoretinal specialist. 
Testing of Relatives at Risk 
Family mutation known. If the disease-causing mutation has been identified in at least one affected family member, it is appropriate to 
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offer molecular genetic testing to at-risk relatives in order to reduce morbidity by early diagnosis and treatment of ophthalmologic 
complications. 
Family mutation not known. If the disease-causing mutation in the family is not known, it is appropriate to offer ophthalmologic 
evaluations to those family members at risk in order to identify individuals who presumably will benefit from regular ophthalmologic 
examinations and early treatment of ophthalmologic complications. 
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes. 
Therapies Under Investigation 
Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be 
clinical trials for this disorder. 
Other 
Genetics clinics are a source of information for individuals and families regarding the natural history, treatment, mode of inheritance, and 
genetic risks to other family members as well as information about available consumer-oriented resources. See the GeneTests Clinic 
Directory. 
Support groups have been established for individuals and families to provide information, support, and contact with other affected 
individuals. The Resources section may include disease-specific and/or umbrella support organizations. 
Genetic Counseling 
Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of 
genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and 
the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, 
cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. To find a genetics or 
prenatal diagnosis clinic, see the GeneTests Clinic Directory. 
Mode of Inheritance 
VCAN-related vitreoretinopathy is inherited in an autosomal dominant manner. 
Risk to Family Members 
Parents of a proband 
z Most individuals diagnosed with VCAN-related vitreoretinopathy have an affected parent. 
z A proband with VCAN-related vitreoretinopathy may have the disorder as the result of a new gene mutation. The proportion 
of cases caused by de novo mutations is not known. 
z Recommendations for the evaluation of parents of a proband with an apparent de novo mutation include ophthalmologic 
evaluation of both parents. Evaluation of parents may determine that one is affected but has escaped previous diagnosis 
because of failure by health care professionals to recognize the syndrome and/or a milder phenotypic presentation. Therefore, 
an apparently negative family history cannot be confirmed until appropriate evaluations have been performed. 
Note: (1) Although most individuals diagnosed with VCAN-related vitreoretinopathy have an affected parent, the family history may appear 
to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or 
late onset of the disease in the affected parent. (2) If the parent is the individual in whom the mutation first occurred, s/he may have 
somatic mosaicism for the mutation and may be mildly/minimally affected. 
Sibs of a proband 
z The risk to the sibs of the proband depends on the genetic status of the proband’s parents. 
z If a parent of the proband has VCAN-related vitreoretinopathy, the risk to the sibs is 50%. 
z When the parents are clinically unaffected and/or the disease-causing mutation found in the proband has not been found in 
the parents, the risk to the sibs of a proband appears to be low. 
z If the disease-causing mutation cannot be found in the proband’s parents, the occurrence of a de novo mutation in the 
proband is presumed. Germline mosaicism has not been described but remains a possibility. 
Offspring of a proband. Each child of an individual with VCAN-related vitreoretinopathy has a 50% chance of inheriting the mutation. 
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Other family members of a proband. The risk to other family members depends on the status of the proband's parents. If a parent is 
found to be affected, his or her family members may be at risk. 
Related Genetic Counseling Issues 
See Testing of Relatives at Risk for information on testing at-risk relatives for the purpose of early diagnosis and treatment. 
Considerations in families with an apparent de novo mutation. When neither parent of a proband with an autosomal dominant 
condition has clinical evidence of the disorder or the mutation found in the proband cannot be found in the DNA of one of the parents, it is 
likely that the proband has a de novo mutation. 
Family planning 
z The optimal time for determination of genetic risk is before pregnancy. 
z It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to 
young adults who are affected or at risk. 
DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing 
methodology and our understanding of genes, mutations, and diseases will improve in the future, consideration should be given to banking 
DNA of affected individuals. DNA banking is particularly relevant when the sensitivity of currently available testing is less than 100%. See  
for a list of laboratories offering DNA banking. 
Prenatal Testing 
No laboratories listed in the GeneTests Laboratory Directory offer molecular genetic testing for prenatal diagnosis of VCAN-related 
vitreoretinopathy. However, prenatal testing may be available for families in which the disease-causing mutation has been identified. For 
laboratories offering custom prenatal testing, see . 
Requests for prenatal testing for conditions such as VCAN-related vitreoretinopathy are not common. Differences in perspective may exist 
among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the 
purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be 
the choice of the parents, discussion of these issues is appropriate. 
Preimplantation genetic diagnosis (PGD) may be available for families in which the disease-causing mutation has been identified. For 
laboratories offering PGD, see . 
Molecular Genetics 
Information in the Molecular Genetics tables is current as of initial posting or most recent update. —ED. 
Table A. Molecular Genetics of VCAN-Related Vitreoretinopathy 
Data are compiled from the following standard references: gene symbol from HUGO; chromosomal locus, 
locus name, critical region, complementation group from OMIM; protein name from Swiss-Prot. 
Table B. OMIM Entries for VCAN-Related Vitreoretinopathy 
Table C. Genomic Databases for VCAN-Related Vitreoretinopathy 
For a description of the genomic databases listed, click here. 
Note: HGMD requires registration. 
Molecular Genetic Pathogenesis 
Gene Symbol Chromosomal Locus Protein Name
VCAN 5q12-q14 Versican core protein
 118661 CHONDROITIN SULFATE PROTEOGLYCAN 2; CSPG2
 143200 WAGNER SYNDROME 1; WGN1
Gene Symbol Entrez Gene
VCAN 118661
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Since VCAN is expressed in many human tissues, mutations in VCAN could be expected to interfere with functions in tissues and organs 
other than the eye; the cardiovascular system in particular would seem a likely candidate, as versican, the protein product of VCAN, is a 
component of the extracellular matrix of the blood vessels [Yao et al 1994, Lemire et al 1999]. A possible explanation for the absence of 
consequences of VCAN mutations in non-ocular tissues is that splicing of the VCAN transcripts may be tissue-specific. 
Normal allelic variants. The genomic region (109,399 nt) of VCAN includes 15 exons (NCBI Genbank accession number NM_004385.3). 
The two largest exons, 7 (2961 nt) and 8 (5262 nt), are subject to alternative splicing, yielding four naturally occurring splice variants 
(named V0, 1, 2, and 3) that exhibit a tissue-specific expression pattern. The respective exon-intron boundaries show the consensus 
sequences for splice acceptor and splice donor sites. 
Pathologic allelic variants. Five different point mutations, all located in conserved splice sites of introns 7 and 8, are associated with the 
phenotype [Miyamoto et al 2005, Kloeckener-Gruissem et al 2006, Meredith et al 2006, Mukhopadhyay et al 2006]. In some cases, identical
mutations have been found in different, unrelated families (Table 2). No exonic mutations have been found. In several patients, it was 
shown that the mutations can lead to aberrant splice products and/or to quantitative changes of the naturally occurring splice variants 
lacking exon 8. 
Table 2. VCAN Pathologic Allelic Variants Discussed in This GeneReview 
1. IVS: Intervening sequence; N>N refers to the respective nucleotide exchange.  
2. VCAN mutations were identified in eight of ten families with vitreoretinopathy. 
DNA Nucleotide Change 1
Protein Amino 
Acid Change
Reference 
Sequence
Number of Families with Mutation 2 
Reference 
c.9265+1 G>A 
(IVS 8 splice donor)
--
NM_004385.3
NP_004376.2
2 
[Kloeckener-Gruissem et al 2006, Meredith et al 2006]
c.4004-1 G>A 
(IVS 7 splice acceptor)
-- 1 
[Mukhopadhyay et al 2006]
c.4004-2 A>G 
(IVS 7 splice acceptor)
-- 1 
[Miyamoto et al 2005]
c.4004-5 T>C 
(IVS 7 splice acceptor)
-- 4 
[Mukhopadhyay et al 2006]
c.4004-5 T>A 
(IVS 7 splice acceptor)
-- 2 
[Mukhopadhyay et al 2006]
Figure 1. Vitreoretinopathy-associated mutations in VCAN and their effects on splice variants and protein isoforms. Under 
normal conditions, differential splicing leads to four transcript variants and protein isoforms V0, V1, V2, or V3, depending 
on the presence of exon 7 (red) and/or exon 8 (green). Attachment of glycosaminoglycan residues (GAGs; black vertical 
lines) modifies the protein to function in water inclusion. Mutations (black single-line vertical arrows pointing downward) 
lead to skipping of exon 8 and yielding increased amounts of variants V2 and V3. The effects of the mutations on isoform 
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expression (decrease or increase) are displayed by wide vertical turquoise-filled arrows (right). An imbalanced quantitative 
ratio of these variants is a result of the mutations. Schematic lines are not drawn to scale. Exon sizes are given in 
nucleotides (nt). Protein isoform length is given by number of amino acid (aa) residues beneath each isoform. c.4004 and 
c.9265 are the first and last nucleotide of exon 8. 
Normal gene product. The extracellular matrix proteoglycan (chondroitin sulfate proteoglycan type 2), also named versican, is found in 
many different tissues in the human body, including the eye [White & Bruzzone 2000]. Four naturally occurring variants accumulate tissue-
specifically. They are products of alternative splicing of exons 7 and 8 (see Figure 1). A central domain of the protein, encoded by both 
exons 7 and 8, carries glycosaminoglycan (GAG) residue modifications, which may be involved in preventing collagen fibrils from sticking 
together and thus ensuring gel-like properties of the vitreous content.
Abnormal gene product. Mutations in splice recognition sequences result in skipping of exon 8 and in the production of aberrant splice 
products [Miyamoto et al 2005, Kloeckener-Gruissem et al 2006, Mukhopadhyay et al 2006]. One consequence is increased accumulation of 
isoforms V2 (no exon 8) and V3 (no exon 7 and 8) [Mukhopadhyay et al 2006] and most likely also of the protein isoforms. This may result 
in severe reduction of GAG modification, which will render the physical properties of the vitreous, leading to a process of premature 
liquefaction. 
Resources 
GeneReviews provides information about selected national organizations and resources for the benefit of the reader. GeneReviews is not 
responsible for information provided by other organizations. Information that appears in the Resources section of a GeneReview is current as
of initial posting or most recent update of the GeneReview. Search GeneTests for this disorder and select  for the most up-to-date Resources
information.—ED. 
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Published Statements and Policies Regarding Genetic Testing 
No specific guidelines regarding genetic testing for this disorder have been developed. 
Chapter Notes 
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